Risdiplam Under FDA Review & How the Lack of SMA Protein May Also Directly Contribute to SMA episode artwork

EPISODE · Mar 16, 2020 · 7 MIN

Risdiplam Under FDA Review & How the Lack of SMA Protein May Also Directly Contribute to SMA

from The Spinal Muscular Atrophy Podcast with Kevin Schaefer · host SMA News Today

Anticipation is growing as Roche/Genentech's treatment risdiplam, the first oral medication to treat SMA, is under FDA review.SMA News Today’s multimedia associate, Price Wooldridge, discusses how the lack of SMA protein may also directly contribute to SMA. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

Episode metadata supplied by the publisher feed · Published Mar 16, 2020

Embed this episode

Ready to play

Risdiplam Under FDA Review & How the Lack of SMA Protein May Also Directly Contribute to SMA

0:00 7:01

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Spinal Muscular Atrophy Podcast with Kevin Schaefer?

This episode is 7 minutes long.

When was this The Spinal Muscular Atrophy Podcast with Kevin Schaefer episode published?

This episode was published on March 16, 2020.

Can I download this The Spinal Muscular Atrophy Podcast with Kevin Schaefer episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!